News
EDA Vice Chairman Witnesses the Official signing and announcement of the technology transfer agreement for the first locally manufactured PCV13 vaccine in Egypt between VBC and Walvax.
Dr. Tamer Elhossieny: An important step toward strengthening national capabilities in biological product manufacturing
We are keen to strengthen cooperation with the World Health Organization and international partners to support the development of the regulatory system.
On behalf of Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), Dr. Tamer Elhossieny, EDA Vice Chairman, participated in the launch event marking the implementation phase of the technology transfer project for manufacturing the Pneumococcal Conjugate Vaccine (PCV13) in Egypt and Africa. The event was held at the Vaccine and Biotechnology City (VBC) in the presence of H.E. Prof. Khaled Abdel-Ghaffar, Minister of Health and Population, in line with Egypt’s strategic direction toward Localization of the manufacturing of strategic pharmaceutical products.
The event was attended by Dr. Hisham Stait, Chairman of the Board of Directors of the Egyptian Authority for Unified Procurement, Medical Supply and Technology Management (UPA); Dr. Amr Kandeel, Deputy Minister of Health and Population for Preventive Medicine, Public Health and Primary Health Care, Ministry of Health and Population; Dr. Hesham Badr, the Vice Chairman of the Unified Procurement Authority (UPA); Dr. Kamal Obeid, Deputy Director of the African Pooled Procurement Mechanism (APPM); and Dr. Nima Abid, WHO representative in Egypt. The event also brought together leaders from relevant national authorities, representatives of international organizations and strategic partners, and pharmaceutical industry representatives, reflecting the importance of coordinated national and international efforts to support local vaccine manufacturing and strengthen health security.
The event included the Official signing and announcement of the technology transfer agreement for the first locally manufactured PCV13 vaccine in Egypt between VBC and Walvax. The agreement aims to facilitate the transfer of advanced technology and develop national manufacturing capabilities in the vaccine sector, thereby enhancing the availability of strategic biological products, securing supply chains, supporting the sustainability of the healthcare system, and opening new opportunities for exports to regional and international markets, particularly African markets.
In his remarks, Dr. Tamer Elhossieny commended the national efforts behind this strategic milestone and the integration of efforts among relevant authorities and international partners to support vaccine manufacturing localization and the transfer of advanced manufacturing technologies to Egypt. He emphasized that the project represents an important step toward strengthening national capabilities in biological product manufacturing, supporting health security, and ensuring the sustainability of strategic vaccine supplies, thereby helping meet citizens’ needs and enhancing the country’s capacity to address challenges associated with global supply chains.
He added that the EDA continues to fulfill its regulatory and oversight role in supporting localization projects by providing the necessary regulatory and technical support and ensuring compliance with the highest standards of quality, safety, and efficacy. This, in turn, supports the competitiveness of locally manufactured products and enhances their prospects for accessing regional and international markets.
Dr. Elhossieny noted that the EDA’s efforts to localize vaccine manufacturing extend beyond the PCV13 project to include support for the localization of several other strategic vaccines, including human papillomavirus (HPV), hepatitis B vaccines for adults and children, measles, rubella, and rotavirus vaccines, alongside other priority vaccines. These efforts aim to diversify local production and support the sustainability of national supplies.
He also reaffirmed the EDA’s continued focus on strengthening cooperation with the WHO and international partners to support the development of the regulatory system, enhance manufacturers’ readiness to operate in accordance with international requirements, and advance toward obtaining WHO prequalification, thereby opening broader opportunities for Egyptian vaccines to enter regional and international markets.
Dr. Elhossieny further explained that the EDA reiterates its ongoing support for the localization of pharmaceutical and biological manufacturing and for strengthening integration between national authorities and international partners. These efforts contribute to achieving health security, expanding local manufacturing capacity, consolidating Egypt’s position as a regional hub for vaccine manufacturing and exports, and supporting African countries in enhancing their production capabilities and achieving greater self-sufficiency in vaccines.
It is worth noting that the Egyptian Drug Authority plays a pivotal role in supporting pharmaceutical manufacturing localization projects through coordination among relevant authorities, monitoring the implementation of priority projects, and working to address potential challenges. These efforts help accelerate implementation and achieve the state’s objectives for localizing strategic pharmaceutical industries in accordance with applicable regulatory requirements and internationally recognized standards.